ArticleAdvances in experimental medicine and biology2023
Epidemiology of Asthma: Prevalence and Burden of Disease.
Article in Advances in experimental medicine and biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Comparison of ICS dose reduction vs. montelukast discontinuation for step-down therapy in well-controlled asthma: a pilot randomized controlled trial.BMC pulmonary medicine · 2025Trial
- AMPK-mediated modulation of JAK2/STAT3 signaling in asthma: a promising target for controlling airway inflammation and remodeling.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Cuproptosis of bronchial epithelial cells triggers airway remodeling in chronic asthma.Scientific reports · 2026Article
- Impact of Overweight and Obesity in Severe Asthma Patients and Its Influence on Achieving Clinical Remission.Journal of asthma and allergy · 2026Article
- Advance in Managing Indoor Cat Allergen Proteins: Molecular Insights, Detection, and Control.International journal of molecular sciences · 2025Review
- Predictive model for inhaled corticosteroid response in hospitalized asthma: implications for precision medicine.Journal of thoracic disease · 2025Article
- Inflammatory lung diseases: a clinical and scientific review of the latest advances and challenges.Pharmacological reports : PR · 2025Review
- The MFGE8/integrin β3 axis mitigates experimental neutrophilic asthma by suppressing NLRP3-Caspase-1 pathway-mediated NETosis.Respiratory research · 2025Article
- AORI-HAP: a multidimensional risk index to predict in-hospital adverse outcomes in asthma exacerbations.Frontiers in medicine · 2025Article
- Interactions between epithelial mesenchymal plasticity, barrier dysfunction and innate immune pathways shape the genesis of allergic airway disease.Expert review of respiratory medicine · 2025Review
- Association of rs7216389 Polymorphism in Gasdermin B (GSDMB) With Childhood Asthma: A Case-Control Study.Cureus · 2025Article
- Expression of NLRP3 in serum and induced sputum of children with asthma and their relationship with disease severity.European journal of medical research · 2024Article
- High ratio of epi-25-(OH)-vitamin D3 to 25-(OH)-vitamin D3 increases the risk of asthma attack in American asthma adults: a population study.BMC public health · 2024Article
- Understanding the determinants of self-reported asthma in Turkey: insights from national data on individual, lifestyle, socioeconomic, and healthcare access factors.BMC pulmonary medicine · 2024Article
- Patient autonomy in self-managing their bronchial asthma exacerbation and its associated factors, 2024.Frontiers in allergy · 2024Article
- Genetic and Pathological Insights into the rs7216389 Polymorphism in Gasdermin B and Its Association with Childhood Asthma.Discoveries (Craiova, Romania)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Asthma, a common airway disease, results in a significant burden to both patients and society worldwide. Yet, despite global political commitment backed by the United Nations, progress to reduce the burden of asthma remains inadequate. This is particularly true in low-income countries. To date, progress has been delayed by the lack of uniform data collection, imperfect surveillance methods, inadequate resources, poor access to effective therapies, substandard asthma education, ineffective governmental policies, rapid urbanization, progressive increase in asthma prevalence, increased life expectancy and obesity rates worldwide, asthma heterogeneity and disease complexity, smoking, and environmental exposures to allergens and pollution. A thorough understanding of the challenges facing the international community is essential to define future strategies to improve the burden of asthma.
Indexed as
Identifiers
37464114What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.